BioSpace News Archive

Introducing the dosing and sequencing strategy for vopratelimab and ipilimumab in ongoing EMERGE Phase 2 trial

Vericel Corporation, a leader in advanced therapies for the sports medicine and severe burn care markets, reported financial results for the third quarter ended September 30, 2019, and recent business highlights.

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today positive preclinical results further elucidating the mechanism of action of BL-8040 in combination with an anti PD-1 and chemotherapy.

The U.S. Food and Drug Administration (FDA) has awarded AnaBios an exclusive Indefinite Delivery Indefinite Quantity (IDIQ) contract to employ adult human primary tissues and cardiomyocytes from organ donors to assess drug safety related to cardiac function.

ChromaCode, Inc., today announced the Company will launch its second highly-multiplexed real-time PCR assay, the HDPCR™ Multi-Drug Resistance (MDR) Panel, and present novel real-time and digital PCR multiplexing data during the upcoming Association for Molecular Pathology (AMP) 2019 Annual Meeting, being held November 6 – 9 in Baltimore, Maryland.

Heska Corporation (NASDAQ: HSKA - News; “Heska” or the “Company”), a provider of advanced veterinary diagnostic and specialty healthcare products, today reported financial results for its third quarter ended September 30, 2019.

Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following investor conferences

Royalty Pharma announced today that it has agreed to pay $330 million to purchase Eisai Co., Ltd.'s royalties on future worldwide sales of tazemetostat, Epizyme Inc.'s (Nasdaq: EPZM) lead investigational agent, outside of Japan, and made an equity investment in Epizyme of $100 million, with options to invest up to an additional $100 million in Epizyme common stock.

Bolt Biotherapeutics, Inc., a private biotechnology company focused on unleashing the power of the immune system to treat cancer, announced the upcoming presentation of preclinical data from its Immune-Stimulating Antibody Conjugate platform at the 34th Annual Meeting of the Society for Immunotherapy of Cancer in National Harbor, Maryland.

IDT Biologika announced that the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, an agency of the United States Department of Health and Human Services, has awarded the company a new Task Order within the 10-year Indefinite Delivery, Indefinite Quantity contract no. HHSN272201800011I to provide process development activities and production of a vaccine against the Respiratory Syncytial Virus.